The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation between VEGF and VEGF-R polymorphisms, toxicity, and clinical outcome in HCC patients receiving sorafenib.
Luca Faloppi
No relevant relationships to disclose
Mario Scartozzi
No relevant relationships to disclose
Maristella Bianconi
No relevant relationships to disclose
Cristian Loretelli
No relevant relationships to disclose
Gianluca Svegliati Baroni
No relevant relationships to disclose
Samuele De Minicis
No relevant relationships to disclose
Alessandra Mandolesi
No relevant relationships to disclose
Riccardo Giampieri
No relevant relationships to disclose
Alessandro Bittoni
No relevant relationships to disclose
Michela Del Prete
No relevant relationships to disclose
Elena Maccaroni
No relevant relationships to disclose
Luca Cecchini
No relevant relationships to disclose
Italo Bearzi
No relevant relationships to disclose
Antonio Benedetti
No relevant relationships to disclose
Stefano Cascinu
No relevant relationships to disclose